TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Lags Revenue Estimates

Company Performance - TScan Therapeutics, Inc. reported a quarterly loss of $0.28 per share, which was better than the Zacks Consensus Estimate of a loss of $0.35, representing an earnings surprise of +20.00% [1] - The company posted revenues of $2.51 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 21.61%, compared to revenues of $1.05 million in the same quarter last year [2] - Over the last four quarters, TScan Therapeutics has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] Stock Performance - TScan Therapeutics shares have declined approximately 59.9% since the beginning of the year, contrasting with the S&P 500's gain of 16.4% [3] - The stock's immediate price movement will largely depend on management's commentary during the earnings call [3] Future Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.35 on revenues of $3.38 million, and for the current fiscal year, it is -$1.32 on revenues of $11.83 million [7] - The estimate revisions trend for TScan Therapeutics was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which TScan Therapeutics belongs, is currently in the top 34% of over 250 Zacks industries, suggesting a favorable outlook for stocks within this sector [8]